RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Alimera Sciences Stock

Alimera Sciences ROCE 2024

Alimera Sciences ROCE

-0.04

Ticker

ALIM

ISIN

US0162592028

WKN

A2PVHE

In 2024, Alimera Sciences's return on capital employed (ROCE) was -0.04, a -107.48% increase from the 0.56 ROCE in the previous year.

Alimera Sciences Aktienanalyse

What does Alimera Sciences do?

Alimera Sciences Inc. is a leading global company specializing in the development of pharmaceutical products for eye diseases. The company was founded in 2003 in Atlanta, Georgia, USA and has since made remarkable progress in developing innovative clinical solutions. Business model: Alimera Sciences Inc. strives to utilize the latest technologies and methods in ophthalmology to improve the quality of life for patients with eye diseases. The company works closely with leading research institutions to incorporate the latest scientific findings into its product development. Alimera Sciences has a wide range of research areas to develop innovative solutions for conditions such as diabetes-related macular degeneration, retinopathy, uveitis, and other eye diseases. The company also places great value on collaboration with the medical community and actively advocates for the improvement of patient care and the education of eye experts. Products: Alimera Sciences' products are specialized in the treatment of eye diseases and utilize various technologies to improve patients' quality of life. The flagship product of Alimera Sciences is Iluvien, an intravitreal implant for the treatment of chronic diabetic macular edema (DME). Iluvien is the only commercially available DME implant and offers a unique treatment option for patients who do not respond to standard treatments. In addition to Iluvien, Alimera Sciences also manufactures a range of other products, including Ozurdex, a steroid-containing intravitreal implant for the treatment of retinopathy and uveitis. Alimera Sciences also has an extensive portfolio of investigational drugs, many of which are in various stages of clinical development. History: Alimera Sciences was founded in 2003 by Daniel C. Myers and David R. Holland in Atlanta, Georgia. The company originally specialized in developing drugs for the treatment of lung diseases, but over the years, its focus shifted to ophthalmology. In 2011, the company received FDA approval for Iluvien, which was a significant milestone in the history of Alimera Sciences. Since then, the company has continuously expanded its presence in ophthalmology by increasing its research and development efforts and forming partnerships with key medical organizations and institutions. Today, Alimera Sciences is a leading provider of pharmaceutical solutions for eye diseases, focusing on the development of drugs to improve patients' quality of life and enhance medical care. Conclusion: Overall, Alimera Sciences is an innovative company specializing in the development of drugs for the treatment of eye diseases. In its 18 years of existence, the company has achieved an impressive success story and continues its efforts to attain a leading position in the ophthalmic industry. With insights and experience in medical history and the knowledge of important medical professionals, the company is prepared to continuously meet the medical needs and expectations of patients with eye diseases. Alimera Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Alimera Sciences's Return on Capital Employed (ROCE)

Alimera Sciences's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Alimera Sciences's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Alimera Sciences's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Alimera Sciences’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Alimera Sciences stock

What is the ROCE (Return on Capital Employed) of Alimera Sciences this year?

The ROCE of Alimera Sciences is -0.04 undefined this year.

How has the ROCE (Return on Capital Employed) of Alimera Sciences developed compared to the previous year?

The ROCE of Alimera Sciences has increased by -107.48% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Alimera Sciences?

A high Return on Capital Employed (ROCE) indicates that Alimera Sciences has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Alimera Sciences?

A low ROCE (Return on Capital Employed) can indicate that Alimera Sciences has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Alimera Sciences impact the company?

An increase in the ROCE of Alimera Sciences can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Alimera Sciences affect the company?

A decrease in ROCE of Alimera Sciences can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Alimera Sciences?

Some factors that can affect Alimera Sciences's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Alimera Sciences so important for investors?

The ROCE of Alimera Sciences is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Alimera Sciences take to improve the ROCE?

To improve the ROCE, Alimera Sciences can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Alimera Sciences pay?

Over the past 12 months, Alimera Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alimera Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Alimera Sciences?

The current dividend yield of Alimera Sciences is .

When does Alimera Sciences pay dividends?

Alimera Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alimera Sciences?

Alimera Sciences paid dividends every year for the past 0 years.

What is the dividend of Alimera Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alimera Sciences located?

Alimera Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alimera Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alimera Sciences from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Alimera Sciences pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Alimera Sciences in the year 2023?

In the year 2023, Alimera Sciences distributed 0 USD as dividends.

In which currency does Alimera Sciences pay out the dividend?

The dividends of Alimera Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Alimera Sciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Alimera Sciences

Our stock analysis for Alimera Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alimera Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.